Atosha and Weill Cornell expand breast cancer drug research



SEATTLE – Biopharmaceutical company Atossa Therapeutics, Inc. (Nasdaq: ATOS) today announced an expanded research agreement with Weill Cornell Medicine to further study antibody-drug conjugates (ADCs) and (Z)-endoxifen Combination treatment of advanced breast cancer. The collaboration builds on earlier in silico research that suggested the drug combination might enhance anti-tumor effects.

The study will investigate the synergy between (Z)-endoxifen, a potent selective estrogen receptor modulator (SERM), and two FDA-approved ADCs, TRODELVY® and ENHERTU®, which are currently For use as monotherapy for metastatic breast cancer. Computer modeling suggests that combining these drugs improves pro-apoptotic effects, which are crucial in cancer treatment because they promote programmed death of cancer cells.

Dr. Steven Quay, Atossa's president and chief executive, said the combination may be more effective than either treatment alone. Upcoming research at Weill Cornell University aims to validate these findings in breast cancer cell culture models. The success of these studies may pave the way for clinical trials in patients with advanced metastatic breast cancer.

(Z)-Endoxifene is well known for its efficacy in patients who have developed resistance to other hormonal treatments. Atossa's proprietary oral formulation of (Z)-endoxifen is designed to bypass liver metabolism and stomach acid, rendering the drug inactive. Ongoing Phase 2 trials are exploring its use in various breast cancer conditions.

This announcement comes as Atossa continues to focus on developing treatments to address significant unmet medical needs in oncology. The company's efforts to advance (Z)-endoxifen are supported by three issued U.S. patents and several pending applications.

3rd party advertising. Not an offer or recommendation by Investing.com.See disclosures here or
Remove ads
.

Press release statements also contain forward-looking statements regarding the potential of (Z)-endoxifen as a breast cancer treatment and its safety. These statements are subject to various risks and uncertainties that could affect actual results and results, including regulatory approvals and the success of ongoing clinical trials.

Atossa's collaboration with Weill Cornell University represents an ongoing commitment to discovering innovative cancer treatments with the ultimate goal of improving outcomes for patients with advanced breast cancer.

Investment Professional Insights

As Atossa Therapeutics, Inc. (NASDAQ: ATOS ) advances research into breast cancer treatments, its financials and market performance have piqued investor interest. Atossa has a market capitalization of $191.72 million, reflecting investors' valuation of the company's potential, according to live data from InvestingPro. Despite profitability challenges, with an adjusted price-to-earnings ratio of -6.97 for the trailing 12 months to the fourth quarter of 2023, the company's shares have seen significant volatility. In the past three months, the total price return has been as high as 76.27%, and in the past year, it has been as high as 139.36%.

InvestingPro Tips highlights that Atossa has more liquid assets than short-term debt, suggesting it has financial flexibility in the short term. This is especially important when the company engages in expensive clinical trials and research collaborations. Additionally, while analysts don't expect to make a profit this year, the company's significant returns last week and strong performance over the past three months and one year suggest investors are confident in its long-term prospects.

For those interested in a more in-depth analysis, InvestingPro has a number of additional tips on Atossa Therapeutics, which can give you further insight into the company's potential. To explore these techniques, visit: https://www.investing.com/pro/ATOS.As a special offer please use coupon code PRONEWS24 Get an additional 10% off with annual or two-year Pro and Pro+ subscriptions, unlocking even more valuable insights.

3rd party advertising. Not an offer or recommendation by Investing.com.See disclosures here or
Remove ads
.

This article was generated with the support of artificial intelligence and reviewed by an editor. For more information, please see our terms and conditions.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *